Current perspectives on therapeutic antibodies |
| |
Authors: | Soomin Yoon Yong-Sung Kim Hyunbo Shim Junho Chung |
| |
Institution: | (1) St. Edmund’s College, University of Cambridge, Cambridge, UK; |
| |
Abstract: | Since the first monoclonal antibody, muromonab-CD3, was approved for therapeutic use in 1986, numerous molecules have been
targeted using therapeutic antibody technology, resulting in 26 therapeutic antibodies being approved by the US FDA as of
November, 2009. Initial concerns regarding antibody drugs focused on immunogenicity, short serum half-life, and weak efficacy.
As the types of antibodies progressed from murine to chimeric, humanized, and fully human antibodies, great progress has been
made in immunogenicity and in vivo instability issues. For example, humanized antibodies, such as bevacizumab, exhibit less than 0.2% immunogenicity and a 20
day serum half-life, which is comparable to native immunoglobulin. Some recently developed antibodies are exceedingly efficacious
and have become first-line therapy for their target diseases. Here, we address and analyze all clinically approved therapeutic
antibodies to date by discussing immunogenicity, half-life, and efficacy. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|